Around 84,000 shares had changed hands on the counter on the BSE, while 3.15 million shares had changed hands on the NSE till 10:15 AM.
Zydus Lifesciences share price soared up to 3.8 per cent at Rs 1156.45 per share on the BSE in Wednesday's intraday deals
The divergence comes as Indian secondary-market stocks are among the priciest in the world, at about 24 times 12-month forward earnings
Bets exceed Rs 65,000 crore even as these firms looked to raise a cumulative Rs 60 crore
The broader markets also showed strength with the BSE MidCap index rising 0.66 per cent at 48,627 levels, while the BSE SmallCap index scaled a new record high at 56,066, jumping 385 points
Release of key macroeconomic numbers, monthly derivatives expiry, and global cues are likely to drive stock market movement this week, according to analysts. Markets will also be reacting to remarks made by the US Federal Reserve Chair Jerome Powell, they said. "This week, we expect the market to witness a gradual up-move with stock-specific action. The focus will shift to monthly F&O expiry as well as global cues. Markets on Monday would react to commentaries of the US Fed Chair at the Jackson Hole Symposium," Siddhartha Khemka, Head of Retail Research, Motilal Oswal Financial Services Ltd, said. US Fed Chair Jerome Powell on Friday signalled that the central bank would cut its interest rate in the September meeting. Powell made a crucial speech that laid the groundwork for future interest rate reductions. Powell said, "The time has come for policy to adjust". "The market has been expecting an interest rate cut during the next Federal Reserve meeting in September. There are ...
As per the bulk deal data available on the BSE, Harindarpal Singh Banga divested over 4 crore shares, or 1.43 per cent stake, in Nykaa at Rs 208.30 apiece, taking the transaction value to Rs 851.50 cr
Private equity major ChrysCapital on Thursday exited Eris Lifesciences by selling its entire 7.27 per cent stake in the company for Rs 1,187 crore via open market transaction, while Infinity Partners picked up shares of the firm. Eris Lifesciences Ltd is a listed Indian pharmaceutical company and a leading player in the domestic branded formulations market. According to the block deal data available on the National Stock Exchange (NSE), ChrysCapital through its affiliate Emerald Investment Ltd sold 98,86,882 shares, amounting to a 7.27 per cent stake in Ahmedabad-based Eris Lifesciences. The shares were disposed of at an average price of Rs 1,201 apiece, taking the transaction value to Rs 1,187.41 crore. These shares were picked up by Infinity Partners at the same price, as per the data on the exchange. Shares of Eris Lifesciences rose 2.13 per cent to close at Rs 1,238.65 apiece on the NSE. Earlier this month, Eris Lifesciences said its consolidated profit after tax declined by
Shares of Divi's Laboratories surged up to 5 per cent at Rs 4960 per share on the BSE in Wednesday's intraday deals
While the buyers and sellers could not be confirmed, General Atlantic Singapore Fund FII Pte Ltd was the likely seller in the housing finance company
Stock Market Highlights on August 20: Bajaj Finserv, IndusInd Bank, Tech M, Bajaj Finance, Kotak Bank, and Axis Bank were the top large-cap gainers, rising up to 3.3 per cent
That's because the country's stock exchanges will stop releasing daily data on overseas fund flows starting Monday, depriving investors of a key sentiment indicator to track the $8.3 trillion market
There is a huge valuation disparity between American and Indian small and midcap stocks despite similar fundamental growth prospects, he says
Other stock market holidays for the year include Gandhi Jayanti on Oct 2, Diwali on Nov 1, Guru Nanak Jayanti on Nov 15, and Christmas on Dec 25
July sees cash levels climb to 5.4%, up from June's 4.6%
Voltas saw strong growth in both UCP (Unitary Cooling product) and EMPS (electro mechanical projects) segments. It reported a profit in EMPS versus expectations of loss
Fresh public doubt necessitates Sebi to conclude its probe and declare findings: petitioner
Experts suggest Chair may have used term loosely
Life Insurance Corporation of India (LIC) MD and CEO Siddhartha Mohanty has said that the corporation is looking to make fresh investments of around Rs 1.30 lakh crore in equities during the current financial year. During April-June FY25, the insurance behemoth made an investment of about Rs 38,000 crore in shares as against Rs 23,300 crore in the same period a year ago. LIC earned a profit of Rs 15,500 crore from its investments in equity markets during the first quarter. The profit from its investment was higher by 13.5 per cent quarter-on-quarter. "We are surely looking at the markets and price movements...we are looking to invest a good amount at least whatever we had invested in last financial year...LIC made an investment of around Rs 1.32 lakh crore in FY'24," he said. Market value of LIC's investment in stocks of various companies stood at around Rs 15 lakh crore at the end of June, he said. LIC has exposure in 282 companies through investment in their shares as of June 30
The heatwave featured no fewer than 80 times in earnings calls for the quarter ended June